Anēmijas ārstēšana

Eritropoēzi stimulējoši līdzekļi

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opens new window)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Avots‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Raksts indeksēts‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opens new window)

Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness. (opens new window)

Arora N, Gupta A, Li HC, Sadeghi N

Avots‎: BMJ Case Rep 2018;11(1):e226497.

Raksts indeksēts‎: PubMed 30567199

DOI‎: 10.1136/bcr-2018-226497

https://pubmed.ncbi.nlm.nih.gov/30567199/ (opens new window)

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (opens new window)

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Avots‎: Am J Hematol 2011;86(9):762-7.

Raksts indeksēts‎: PubMed 21850658

DOI‎: 10.1002/ajh.22111

https://www.ncbi.nlm.nih.gov/pubmed/21850658 (opens new window)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (opens new window)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Avots‎: Acta Haematol 2007;117(3):162-7.

Raksts indeksēts‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (opens new window)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (opens new window)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Avots‎: Am J Hematol 2013;88(12):990-6.

Raksts indeksēts‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (opens new window)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (opens new window)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Avots‎: J Clin Oncol 2011;29(28):3791-7.

Raksts indeksēts‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (opens new window)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (opens new window)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Avots‎: Cancer 2012;118(3):848-55.

Raksts indeksēts‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (opens new window)

Management of anemia in cancer patients. (opens new window)

Calabrich A, Katz A.

Avots‎: Future Oncol 2011;7(4):507-17.

Raksts indeksēts‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (opens new window)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (opens new window)

Chojnowski K, Trelinski J.

Avots‎: Acta Haematol Pol 2007;38(4):479-84.

Raksts indeksēts‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (opens new window)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (opens new window)

Deger M, Eisterer W, Kutikova L, Salek S.

Avots‎: Support Care Cancer 2013;21(2):485-93.

Raksts indeksēts‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (opens new window)

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. (opens new window)

Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U

Avots‎: Lancet Haematol 2024;11(9):e646-58.

Raksts indeksēts‎: PubMed 39038479

DOI‎: 10.1016/S2352-3026(24)00203-5

https://pubmed.ncbi.nlm.nih.gov/39038479/ (opens new window)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (opens new window)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Avots‎: BJU Int 2011;108(10):1582-7.

Raksts indeksēts‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (opens new window)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (opens new window)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Avots‎: J Clin Oncol 2010;28(13):2239-45.

Raksts indeksēts‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (opens new window)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (opens new window)

Ford PA, Grant SJ, Mick R, Keck G.

Avots‎: J Clin Oncol 2015;33(15):1674-9.

Raksts indeksēts‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (opens new window)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (opens new window)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Avots‎: Br J Cancer 2011;105(9):1267-72.

Raksts indeksēts‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (opens new window)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (opens new window)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Avots‎: J Intern Med 2017;281(3):284-99.

Raksts indeksēts‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (opens new window)

How I treat cancer-associated anemia. (opens new window)

Gilreath JA, Rodgers GM

Avots‎: Blood 2020;136(7):801-13.

Raksts indeksēts‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opens new window)

Update on safety of ESAs in cancer-induced anemia. (opens new window)

Glaspy J.

Avots‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Raksts indeksēts‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (opens new window)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opens new window)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Avots‎: Eur J Haematol. 2023 110(4):354-61.

Raksts indeksēts‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opens new window)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (opens new window)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Avots‎: Int J Hematol 2015;102(4):401-12.

Raksts indeksēts‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (opens new window)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Avots‎: Cancer 2013;119(1):107-14.

Raksts indeksēts‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (opens new window)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Avots‎: J Natl Cancer Inst 2013;105(14):1018-26.

Raksts indeksēts‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (opens new window)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (opens new window)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Avots‎: Cancer Sci 2013;104(4):481-5.

Raksts indeksēts‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (opens new window)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (opens new window)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Avots‎: Br J Haematol 2019;184(2):134-60.

Raksts indeksēts‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (opens new window)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opens new window)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Avots‎: Support Care Cancer 2012;20(1):159-65.

Raksts indeksēts‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opens new window)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opens new window)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Avots‎: Leuk Lymphoma. 2019;60(9):2324-7.

Raksts indeksēts‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opens new window)

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. (opens new window)

Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM

Avots‎: Lancet 2024;403(10423):249-60.

Raksts indeksēts‎: PubMed 38048786

DOI‎: 10.1016/S0140-6736(23)01724-5

https://pubmed.ncbi.nlm.nih.gov/38048786/ (opens new window)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (opens new window)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Avots‎: Oncologist 2010;15(9):935-43.

Raksts indeksēts‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (opens new window)

The effect of erythropoiesis-stimulating agents on lung cancer patients: a meta-analysis. (opens new window)

Tong Z, Xu Z, Duan Y, Sun X, Qi B

Avots‎: Clin Exp Med 2024;24(1):150.

Raksts indeksēts‎: PubMed 38967734

DOI‎: 10.1007/s10238-024-01391-3

https://pubmed.ncbi.nlm.nih.gov/38967734/ (opens new window)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (opens new window)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Avots‎: Lung Cancer 2012;76(3):478-85.

Raksts indeksēts‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (opens new window)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (opens new window)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Avots‎: Eur J Haematol 2016;97(1):33-8.

Raksts indeksēts‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (opens new window)

Intravenozā dzelzs

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opens new window)

Avots‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Raksts indeksēts‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opens new window)

Intravenous iron in oncology. (opens new window)

Auerbach M, Ballard H.

Avots‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Raksts indeksēts‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (opens new window)

Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (opens new window)

Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A

Avots‎: J Clin Med. 2022;11(14):4156.

Raksts indeksēts‎: PubMed 35887920

DOI‎: 10.3390/jcm11144156

https://pubmed.ncbi.nlm.nih.gov/35887920/ (opens new window)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (opens new window)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Avots‎: Int J Colorectal Dis 2016;31(3):543-51.

Raksts indeksēts‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (opens new window)

How I treat cancer-associated anemia. (opens new window)

Gilreath JA, Rodgers GM

Avots‎: Blood 2020;136(7):801-13.

Raksts indeksēts‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opens new window)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (opens new window)

Gilreath JA, Stenehjem DD, Rodgers GM.

Avots‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Raksts indeksēts‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (opens new window)

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (opens new window)

Henry DH, Dahl NV, Auerbach MA.

Avots‎: Am J Hematol 2012;87(3):308-10.

Raksts indeksēts‎: PubMed 22262486

DOI‎: 10.1002/ajh.22262

https://www.ncbi.nlm.nih.gov/pubmed/22262486 (opens new window)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opens new window)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Avots‎: Eur J Haematol. 2023 110(4):354-61.

Raksts indeksēts‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opens new window)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (opens new window)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Avots‎: Curr Oncol. 2023 24;30(9):7836-51.

Raksts indeksēts‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (opens new window)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (opens new window)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Avots‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Raksts indeksēts‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (opens new window)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (opens new window)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Avots‎: World J Gastroenterol 2014;20(8):1972-85.

Raksts indeksēts‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (opens new window)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (opens new window)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Avots‎: South Asian J Cancer. 2023 15;12(2):93-9.

Raksts indeksēts‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (opens new window)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (opens new window)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Avots‎: J Clin Oncol 2008;26(10):1619-25.

Raksts indeksēts‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (opens new window)